Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
86M
-
Number of holders
-
489
-
Total 13F shares, excl. options
-
40.6M
-
Shares change
-
-1.43M
-
Total reported value, excl. options
-
$6.57B
-
Value change
-
-$213M
-
Put/Call ratio
-
1.18
-
Number of buys
-
271
-
Number of sells
-
-173
-
Price
-
$161.89
Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q2 2021
583 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q2 2021.
CRISPR Therapeutics AG - Common Stock (CRSP) has 489 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 40.6M shares
of 86M outstanding shares and own 47.2% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (7.78M shares), Capital International Investors (4.59M shares), Nikko Asset Management Americas, Inc. (3.38M shares), NEA Management Company, LLC (1.59M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.19M shares), MACQUARIE GROUP LTD (1.16M shares), BlackRock Inc. (1.05M shares), Bellevue Group AG (967K shares), CREDIT SUISSE AG/ (961K shares), and LOOMIS SAYLES & CO L P (909K shares).
This table shows the top 489 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.